[go: up one dir, main page]

TN2015000156A1 - Dispersible tablet - Google Patents

Dispersible tablet

Info

Publication number
TN2015000156A1
TN2015000156A1 TNP2015000156A TN2015000156A TN2015000156A1 TN 2015000156 A1 TN2015000156 A1 TN 2015000156A1 TN P2015000156 A TNP2015000156 A TN P2015000156A TN 2015000156 A TN2015000156 A TN 2015000156A TN 2015000156 A1 TN2015000156 A1 TN 2015000156A1
Authority
TN
Tunisia
Prior art keywords
dispersible tablet
tablet
nimorazole
dispersion
patient
Prior art date
Application number
TNP2015000156A
Other languages
French (fr)
Inventor
Dumbre Nilesh Tanhaji
Bhadgale Mahesh Mohanrao
Bafna Vardhaman Chandrakant
Original Assignee
Azanta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK201270714A external-priority patent/DK177906B1/en
Priority claimed from US13/680,216 external-priority patent/US8703188B1/en
Application filed by Azanta As filed Critical Azanta As
Publication of TN2015000156A1 publication Critical patent/TN2015000156A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a tablet comprising Nimorazole. ln particular, the invention concerns a pharmaceutical composition or a tablet comprising Nimorazole or a pharmaceutically acceptable sait thereof, for dispersion in water and administration via a tube to a patient with swallowing difficulties.
TNP2015000156A 2012-11-19 2015-04-22 Dispersible tablet TN2015000156A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK201270714A DK177906B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
US13/680,216 US8703188B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
PCT/DK2013/050384 WO2014075692A1 (en) 2012-11-19 2013-11-18 Dispersible tablet

Publications (1)

Publication Number Publication Date
TN2015000156A1 true TN2015000156A1 (en) 2016-10-03

Family

ID=49683383

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000156A TN2015000156A1 (en) 2012-11-19 2015-04-22 Dispersible tablet

Country Status (12)

Country Link
EP (1) EP2919754A1 (en)
JP (1) JP2015537013A (en)
AU (1) AU2013347264B2 (en)
BR (1) BR112015011408A2 (en)
CA (1) CA2888856A1 (en)
EA (1) EA201590732A1 (en)
MX (1) MX2015006217A (en)
NZ (1) NZ707033A (en)
RU (1) RU2015117921A (en)
TN (1) TN2015000156A1 (en)
WO (1) WO2014075692A1 (en)
ZA (1) ZA201502896B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3250182T3 (en) * 2015-01-27 2023-06-28 Janssen Pharmaceutica Nv Dispersible compositions
MX374909B (en) 2015-04-01 2025-03-06 Akebia Therapeutics Inc THE USE OF HYPOXIA INDUCIBLE FACTOR (HIF) PROPYL HYDROLASE INHIBITOR FOR THE TREATMENT OR PREVENTION OF ANEMIA.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2652300A1 (en) * 2006-05-15 2007-11-22 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
JP2008081448A (en) * 2006-09-28 2008-04-10 Kowa Pharmaceutical Co Ltd Zolpidem tartrate bitterness masking immediate release particles
US20080131467A1 (en) * 2006-11-30 2008-06-05 Dennis Nelson Film-coated solid dosage form
TR201901905T4 (en) * 2009-12-11 2019-03-21 Sumitomo Dainippon Pharma Co Ltd Dry coated orodispersible tablet.
KR20130100892A (en) * 2010-04-14 2013-09-12 유파마 피티와이 엘티디 Radiation sensitiser compositions

Also Published As

Publication number Publication date
JP2015537013A (en) 2015-12-24
RU2015117921A (en) 2017-01-10
NZ707033A (en) 2016-11-25
AU2013347264B2 (en) 2016-10-27
EA201590732A1 (en) 2016-01-29
EP2919754A1 (en) 2015-09-23
BR112015011408A2 (en) 2017-07-11
ZA201502896B (en) 2016-11-30
WO2014075692A1 (en) 2014-05-22
CA2888856A1 (en) 2014-05-22
AU2013347264A1 (en) 2015-05-07
MX2015006217A (en) 2015-11-16

Similar Documents

Publication Publication Date Title
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
HK1218560A1 (en) Compositions and methods
NZ702663A (en) Nuclear transport modulators and uses thereof
MX369121B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
MX348823B (en) Stable formulations of linaclotide.
MX366090B (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
TN2015000135A1 (en) Modified release formulations for oprozomib
PH12012502082A1 (en) Combination of active loaded granules with additional actives
IN2013MU00711A (en)
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
MX2012001691A (en) Orally disintegrating compositions of linaclotide.
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
TN2015000267A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX363389B (en) Pharmaceutical composition comprising amorphous ivabradine.
IN2015DN02999A (en)
TN2015000156A1 (en) Dispersible tablet
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.
MX2012013178A (en) Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics.
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
MY197454A (en) Non-enteric pharmaceutical composition comprising crofelemer
SA515360445B1 (en) Dispersible tablet
DK201270714A (en) Dispersible tablet
UA56353U (en) method for restoration of tear-nasal canal in children with administration of drug
UA105513C2 (en) Glucosamine prolonged release dosage form
CA2864049A1 (en) Use of beta-nerve growth factor for inducing ovulation in mammals